Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.

Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.

The study is conducted to investigate the pharmacokinetics of Doripenem during CVVHDF (Continuous venovenous hemodiafiltration), MARS (Molecular Adsorbent Recirculating System) and intermittent hemodialysis.

Inclusion Criteria:

• Age >18 years
• Suspected or proven bacterial infection requiring parenteral antibiotic therapy.
• Organ replacement therapy (MARS, CVVHDF or HD)

Exclusion Criteria:

• Known hypersensitivity to doripenem or other carbapenems, or severe hypersensitivity (anaphylactic reaction) to beta-lactam antibacterial agents.
• An expected survival of less than two days.
• Known pregnancy
• Coadministration of valproic acid or probenecid, which cannot be discontinued for the duration of the study
• Doripenem as monotherapy for resistent species or fungal infections.
• Other reasons opposing the study participation on the discretion of the investigators.